199 related articles for article (PubMed ID: 27310704)
41. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers.
An B; Kondo Y; Okamoto Y; Shinjo K; Kanemitsu Y; Komori K; Hirai T; Sawaki A; Tajika M; Nakamura T; Yamao K; Yatabe Y; Fujii M; Murakami H; Osada H; Tani T; Matsuo K; Shen L; Issa JP; Sekido Y
Int J Cancer; 2010 Nov; 127(9):2095-105. PubMed ID: 20131317
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
43. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
44. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H
Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
[TBL] [Abstract][Full Text] [Related]
46. CpG island methylator phenotype and its relationship with prognosis in adult acute leukemia patients.
Fu HY; Wu DS; Zhou HR; Shen JZ
Hematology; 2014 Sep; 19(6):329-37. PubMed ID: 24164743
[TBL] [Abstract][Full Text] [Related]
47. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
48. Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- and gene-specific scoring alternatives on recommended multi-gene panels.
Berg M; Hagland HR; Søreide K
PLoS One; 2014; 9(1):e86657. PubMed ID: 24466191
[TBL] [Abstract][Full Text] [Related]
49. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer.
Worthley DL; Whitehall VL; Buttenshaw RL; Irahara N; Greco SA; Ramsnes I; Mallitt KA; Le Leu RK; Winter J; Hu Y; Ogino S; Young GP; Leggett BA
Oncogene; 2010 Mar; 29(11):1653-62. PubMed ID: 19966864
[TBL] [Abstract][Full Text] [Related]
50. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.
Nosho K; Shima K; Kure S; Irahara N; Baba Y; Chen L; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2009 Jan; 11(1):87-95. PubMed ID: 19107235
[TBL] [Abstract][Full Text] [Related]
51. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
Ogino S; Nosho K; Irahara N; Meyerhardt JA; Baba Y; Shima K; Glickman JN; Ferrone CR; Mino-Kenudson M; Tanaka N; Dranoff G; Giovannucci EL; Fuchs CS
Clin Cancer Res; 2009 Oct; 15(20):6412-20. PubMed ID: 19825961
[TBL] [Abstract][Full Text] [Related]
52. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
53. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
English DR; Young JP; Simpson JA; Jenkins MA; Southey MC; Walsh MD; Buchanan DD; Barker MA; Haydon AM; Royce SG; Roberts A; Parry S; Hopper JL; Jass JJ; Giles GG
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1774-80. PubMed ID: 18628431
[TBL] [Abstract][Full Text] [Related]
54. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
[TBL] [Abstract][Full Text] [Related]
55. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
56. Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.
Koh YW; Chun SM; Park YS; Song JS; Lee GK; Khang SK; Jang SJ
Tumour Biol; 2016 Aug; 37(8):10675-84. PubMed ID: 26867769
[TBL] [Abstract][Full Text] [Related]
57. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.
Chang MS; Uozaki H; Chong JM; Ushiku T; Sakuma K; Ishikawa S; Hino R; Barua RR; Iwasaki Y; Arai K; Fujii H; Nagai H; Fukayama M
Clin Cancer Res; 2006 May; 12(10):2995-3002. PubMed ID: 16707594
[TBL] [Abstract][Full Text] [Related]
58. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
59. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
60. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.
Overman MJ; Morris V; Moinova H; Manyam G; Ensor J; Lee MS; Eng C; Kee B; Fogelman D; Shroff RT; LaFramboise T; Mazard T; Feng T; Hamilton S; Broom B; Lutterbaugh J; Issa JP; Markowitz SD; Kopetz S
Oncotarget; 2016 Oct; 7(41):67495-67506. PubMed ID: 27542211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
